Navigation Links
The Launch of Three New Parkinson's Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
Date:7/30/2013

BURLINGTON, Mass., July 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of key current brands and the launch of three new therapies will help sustain the Parkinson's disease (PD) market throughout the 2012-2022 forecast period, despite growing competition from generics. As a result of these competing forces, total sales of therapies used to treat PD will remain relatively flat over the next decade, beginning at $2.3 billion in 2012 and ending at $2.4 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Parkinson's Disease finds that dopamine agonists will maintain the largest class-level market share through 2022 at approximately 30 percent. For the drug-class leaders pramipexole (Boehringer Ingelheim's Mirapex, other brands, generics; Mirapex ER, other brands) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL, other brands, generics), growing reliance on convenient once-daily formulations is expected to render the original, three-times-daily formulations nearly obsolete by the second half of the 2012-2022 forecast period. Similarly, the use of the once-daily, transdermal product rotigotine (UCB/Otsuka Pharmaceutical's Neupro, other brands) will continue to grow within the class, primarily outside of Europe, following its 2012 U.S. market re-entry and 2013 launch in Japan.

The findings also reveal that the launch of three emerging therapies through 2015 will provide useful treatment alternatives in PD. Impax Laboratories' Rytary, a reformulation of levodopa (multiple brands, generics), is expected to be prescribed, at least initially, in more-advanced patients experiencing periods of "off" time but will compete with established levodopa-adjunct therapies including the catechol-O-methyltransferase inhibitor entacapone (Novartis/Orion Pharma's Comtan/Stalevo, other brands, generics). Third-to-market monoamine oxidase-B inhibitor safinamide (Newron Pharmaceuticals/Zambon Pharma/Meiji Seika Pharma) has proved effective both in early PD and as an adjunct to levodopa in more advanced patients but will contend with the class leader rasagiline (Teva/Lundbeck's Azilect). Lastly, Acadia Pharmaceuticals' inverse agonist of 5-HT2A receptors pimavanserin is poised to become the first therapy approved specifically to treat psychotic symptoms associated with PD (a key comorbidity), but will likely compete with current antipsychotic agents that are used off-label with some clinical success today. All three of these emerging agents will face intensifying competition from generic alternatives within their respective market segments.

"The late-stage PD therapy pipeline is populated with a range of symptomatic agents targeting niche populations, but, as such, these products may have more-restricted commercial potential," said Decision Resources Senior Business Insights Analyst Nadja Rozovsky, Ph.D. "Delaying disease progression remains the greatest unmet need in the treatment of PD, but it is one that is still far from realization."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Using Success & Failure Roadmap Paves the Way for Positive New Product Launches in Oncology
2. Indegene builds on Aptilon acquisition to launch new iMCM framework for enhanced Enterprise-wide Multichannel Marketing (MCM) deployment.
3. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
4. ProteinSimple Launches Multimode Imager with IR Capability
5. Primal Pictures Launches Functional Anatomy for Movement & Injuries (FAMI) App Series for Health and Fitness Professionals
6. Glenmark Pharmaceuticals Announces Launch of its Child Health CSR Programme in Kenya
7. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
8. A*STARs SIMTech and NUS Faculty of Engineering Launch Joint Labs to Boost Manufacturing Productivity
9. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
10. Products From Eight Health-IT Vendors First to Receive Certification Under New Program Launched by IHE USA and ICSA Labs
11. HORIBA Scientific Launches New Raman ParticleFinder Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a clinical ... through treatment, today announced that Carmine N. Stengone , president ... at the Needham & Company 16 th Annual Healthcare Conference ... PDT) at the Westin Grand Central Hotel in New ... ...
(Date:3/29/2017)... , March 29, 2017 Today, CVS Health ... Kim Reynolds , Department of Public Health Director ... Steve Lukan in announcing the availability of the ... Pharmacy locations in Iowa.  CVS Health has established a standing ... allows CVS Pharmacy to expand access to the medication in ...
(Date:3/29/2017)... CREEK, Calif. , Mar 29, 2017 /PRNewswire/ ... cervical-fusion technology, announced the addition of two industry ... Lynch has joined the company to lead ... assuming International leadership.  Together, Mr. Lynch and Mr. ... experience.  Mr. Lynch joins the ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Full Contact K9, an Atlanta-based dog ... Protect Law that assists dog owners in creating legally-enforceable pet trusts for their ... the natural next step to protect their new companion. Says Evan Dunbar, CEO of ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC TITLE ... the official title sponsor of the Baltimore Women’s Classic, the largest all women’s 5K ... walk or run the course around the Baltimore Inner Harbor. Mercy has been the ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, ... Spice", it has been used for thousands of years. , "The West has caught ... of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, ... prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , ... as the visionary leader in the training of physicians, scientists, and members of ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental team ... patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain ... the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton ...
Breaking Medicine News(10 mins):